Penn Medicine 2-PREVENT Breast Cancer TCE

Breast Cancer Translational Center of Excellence (TCE) @PennCancer focusing on recurrence prevention and expanding access to clinical trials for breast cancer

[Penn Medicine 2-PREVENT Breast Cancer TCE @PennBreastTCE]

The 2-PREVENT Breast Cancer TCE at @PennMedicine tackles relapse head-on. By monitoring and treating minimal residual disease, we’re redefining survivorship. Empowering patients and enhancing access to clinical trials, we’re committed to making a difference! #BCSM

[The Philadelphia Citizen @thephilacitizen]

Penn Medicine's large-scale breast cancer clinical trial is testing different drug combinations to keep sleeper cells at bay. Since 2017, they have worked with hundreds of breast cancer patients from across the nation with promising results.
https://t.co/jKcalY4WyO

[Penn Medicine Cancer @PennCancer]

Four federally funded studies led by Penn faculty were selected for this year’s @CRForumUS Top 10 Clinical Research Achievement Awards, including a @NatureMedicine paper from Dr. @AngieDemichele and Lewis Chodosh, MD, PhD: https://t.co/nuTbCm4sDu

[The Daily Pennsylvanian @dailypenn]

Four Perelman School of Medicine studies are set to receive the Clinical Research Forum’s Top 10 Clinical Research Achievement Awards.

https://t.co/E4mefGD011

[nature @Nature]

Researchers are targeting dormant tumour cells that might explain why some cancers reappear long after successful treatment

https://t.co/hImJjFmNnI

[Penn Medicine 2-PREVENT Breast Cancer TCE @PennBreastTCE]

@OncologyTimes article featuring an essay by Drs @AngieDemichele and Lewis Chodosh (@Penn_CBIO) on how they developed an approach to target dormant breast cancer cells & translated this groundbreaking lab research into a clinical trial. @PennCancer @PennMedicine

[Oncology Times @OncologyTimes]

The December issue is out now! It features Killing #Cancer in Its Sleep, Teaching the Next Generation of #Oncologists & #Hematologists, Rates of #AppendixCancer Increasing in Younger Adults, and more. Read it here: https://t.co/ZiTsuEj7I4

[PennSurgery @pennsurgery]

To wrap up #BreastCancerAwarenessMonth, @SueSerioFox29 sat down with her surgeon, Dr.Julia Tchou, to discuss the latest in #BreastCancer screening, treatment & research. Also featured ⁦@AngieDemichele⁩ on preventing recurrence. ⁦@FOX29philly⁩ https://t.co/pS4YlKWhim

[Penn Medicine Cancer @PennCancer]

In a phase III trial, adjuvant treatment with a CDK4/6 inhibitor significantly improved OS in high-risk early breast cancer. Dr. @AngieDemichele emphasized the invasive DFS benefits of these drugs but noted that questions still remain. @medpagetoday https://t.co/9FzOlQPhxU

[Penn Medicine 2-PREVENT Breast Cancer TCE @PennBreastTCE]

We will be at the She Shine’s conference this Saturday 11/1/25 from 9am-4:30pm at New Covenant Church of Philadelphia in Germantown! #celebratingsisterhood

[Penn Medicine @PennMedicine]

A clinical trial led by @AngieDemichele and Dr. Lewis Chodosh has shown it’s possible to identify breast cancer survivors at higher risk of recurrence due to the presence of dormant cancer cells, and to effectively treat these cells with repurposed drugs. https://t.co/jWKlTnRacK

[Penn Medicine 2-PREVENT Breast Cancer TCE @PennBreastTCE]

@AngieDemichele joins @CBSNews to discuss dormant tumor cells, breast cancer recurrence, and the CLEVER trial @PennMedicine @PennCancer . Check it out here: https://t.co/UFeH6015tZ

[Penn Medicine 2-PREVENT Breast Cancer TCE @PennBreastTCE]

@AngieDemichele joins @CBSNews to discuss dormant tumor cells, breast cancer recurrence, and the CLEVER trial @PennMedicine @PennCancer . Check it out here: https://t.co/UFeH6015tZ

[Penn Medicine Cancer @PennCancer]

Dr. @AngieDemichele joined @FOX29philly to discuss a clinical trial for preventing cancer recurrence & how it’s helped the study’s participants, like breast cancer survivor Illeana Casiano-Vazquez, feel more in control of their future. @PennBreastTCE https://t.co/vIUEt4FrN7

[Angie DeMichele, MD, MSCE, FASCO @AngieDemichele]

Huge thanks to @FOX29Philly for having Illeana and me on Good Day Philadelphia to talk about recurrent breast cancer, dormancy, the CLEVER trial, and of course her incredible survivor story. We had such a great time!

[Penn Medicine @PennMedicine]

.@AngieDemichele joined @FOX29philly to discuss a clinical trial for preventing cancer recurrence, and how it’s helped the study’s participants, like breast cancer survivor Illeana Casiano-Vazquez, feel more in control of their future. @PennBreastTCE https://t.co/XwqRU793NL

[Penn Medicine 2-PREVENT Breast Cancer TCE @PennBreastTCE]

Our own @AngieDemichele and breast cancer survivor Illeana Casiano-Vazquez joined @FOX29Philly to talk about dormant breast cancer cells and the @PennMedicine CLEVER trial. Watch the full segment here: https://t.co/eN9WRY8L7t

[Penn Medicine CSO @PennMedCSO]

A 1st-of-its-kind clinical trial identified risk of breast cancer recurrence & successfully treated dormant tumor cells using existing drugs ft. @AngieDemichele (@PennCancer) & Lewis Chodosh (@Penn_CBIO) https://t.co/twZ1RIlxjm

[Penn Medicine Cancer @PennCancer]

A newly published first-of-its-kind clinical trial identified risk of #BreastCancer recurrence and successfully treated dormant tumor cells using existing drugs. The research, led by @PennCancer's Dr. @AngieDemichele, was published in @NatureMedicine. https://t.co/xypbWJzigX

[WHYY News @WHYYNews]

Doctors call them sleeper cells, tiny pockets of dormant breast cancer that can reawaken years later.
Penn Medicine researchers say they’ve found a way to find them and wipe them out with existing drugs and leave more survivors staying cancer-free.

Read: https://t.co/ISgrS41kBV

[Penn Medicine @PennMedicine]

A newly published first-of-its-kind clinical trial identified risk of breast cancer recurrence and successfully treated dormant tumor cells using existing drugs.

The research, led by @PennCancer's @AngieDeMichele, was published today in @NatureMedicine. https://t.co/XM4AE7ggF9

[Penn Medicine 2-PREVENT Breast Cancer TCE @PennBreastTCE]

New proof-of-concept trial by @PennMedicine in @NatureMedicine researched dormant DTCs link to breast cancer recurrence. The CLEVER trial showed HCQ and EVE reduced DTCs & improved recurrence-free survival. Read more here 🔗: https://t.co/sZMrgipW46